INS and type 2 diabetes mellitus: On the other hand, nateglinide, a short-acting insulin secretagogue, failed to show a reduction in progression to T2DM in patients with IGT [79], suggesting that the therapeutic strategy to increase beta cell workload may not be effective to prevent deterioration of glucose metabolism.